Medindia

X

Elsevier Announces 2007 Journal Impact Factor Highlights

Friday, June 27, 2008 General News J E 4
Advertisement
AMSTERDAM, June 26

- 43 Elsevier Journals Receive Top Category Rank; Journal Citations Grow10 Percent; Lancet and Cell Each Increase and Retain Leadership Positions

Elsevier, the leading publisher of scientific, technical and medicalinformation products and services, today announced highlights of its JournalImpact Factor performance in 2007. The 2007 Journal Citation Reports(c)published by ThomsonReuters, reports that 43 Elsevier journals ranked numberone in their respective categories. In addition, total Elsevier journalcitations grew by 10 percent (compared to an industry average of 8.9 percent).

In addition, Elsevier's flagship journals, Cell and The Lancet, bothincreased in impact factor: Cell jumped to 29.887 (#1 research journal inCell Biology) and The Lancet improved by 2.8 points to 28.6.

The impact factor is a measure of the frequency with which the averagearticle in a journal has been cited in a particular year. The impact factorhelps to evaluate a journal's relative importance, especially when comparedwith others in the same field.

Glen Campbell, Senior Vice President of U.S. Health Sciences Journalssaid, "Our impact factors performance is a strong sign that our continuedeffort to publish trusted, leading-edge STM information is contributingsignificantly to the continuous cycle of discovery and progress. Theseresults reflect the truly dedicated efforts of our editors, authors,reviewers and publishing staff."

"We are very proud of the strong showing for Elsevier's journals thisyear both in impact factors and total number of article citations," remarkedMartin Tanke, Managing Director of Science and Technology Journals. "Thiswould not have been possible without our 7,000 editors who have helped toguide and build their journals. Building world class content in partnershipwith our authors, editors and publishing is one of our foremost goals."

Some of the journals that led their respective categories include:Journal of the American Medical Informatics Association (#1 in MedicalInformatics); Pain (#1 in Anesthesiology); Annals of Emergency Medicine (#1in Emergency Medicine); Journal of Allergy & Clinical Immunology (#1 inAllergy); Water Research (#1 in Water Resources); Trends in Ecology &Evolution (#1 in Evolutionary Biology); Biomaterials (#1 in MaterialsScience, Biomaterials); Cognitive Brain Research (#1 in Computer Science,Artificial Intelligence); Lancet Infectious Diseases (#1 in InfectiousDiseases); Lancet Neurology (#1 in Clinical Neurology); and Progress inPolymer Science (#1 in Polymer Science).

About Elsevier

Elsevier is a world-leading publisher of scientific, technical andmedical information products and services. Working in partnership with theglobal science and health communities, Elsevier's 7,000 employees in over 70offices worldwide publish more than 2,000 journals and 1,900 new books peryear, in addition to offering a suite of innovative electronic products, suchas ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered inAmsterdam, The Netherlands and has offices worldwide. Elsevier is part ofReed Elsevier Group plc (http://www.reedelsevier.com/), a world-leadingpublisher and information provider. Operating in the science and medical,legal, education and business-to-business sectors, Reed Elsevier provideshigh-quality and flexible information solutions to users, with increasingemphasis on the Internet as a means of delivery. Reed Elsevier's tickersymbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK andENL (New York Stock Exchange).Contact: Tom Reller, +1-212-462-1912, t.reller@elsevier.com ; Ylann Schemm, +31-20-485-2025, y.sche
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Alimera Reports Results From the Three-Month Inter...
S
Impliant Restarts European Clinical Activities for...